 | • レポートコード：TPM-C03043 • 出版社/出版日：Transparency Market Research / 2019年1月22日 • レポート形態：英文、PDF、183ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、肝炎治療の世界市場について調べ、肝炎治療の世界規模、市場動向、市場環境、タイプ別（A型肝炎、B型肝炎、C型肝炎）分析、薬剤クラス別（ヌクレオチドアナログ逆転写酵素阻害剤、NS5A阻害剤、マルチクラス併用剤、ヌクレオチドアナログNS5Bポリメラーゼ阻害剤、インターフェロン・リバビリン）分析、流通経路別（院内薬局、小売薬局、オンライン薬局）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・肝炎治療の世界市場動向 ・肝炎治療の世界市場環境 ・肝炎治療の世界市場規模 ・肝炎治療の世界市場規模：タイプ別（A型肝炎、B型肝炎、C型肝炎） ・肝炎治療の世界市場規模：薬剤クラス別（ヌクレオチドアナログ逆転写酵素阻害剤、NS5A阻害剤、マルチクラス併用剤、ヌクレオチドアナログNS5Bポリメラーゼ阻害剤、インターフェロン・リバビリン） ・肝炎治療の世界市場規模：流通経路別（院内薬局、小売薬局、オンライン薬局） ・肝炎治療の世界市場：地域別市場規模・分析 ・肝炎治療の北米市場規模・予測 ・肝炎治療のアメリカ市場規模・予測 ・肝炎治療の中南米市場規模・予測 ・肝炎治療のヨーロッパ市場規模・予測 ・肝炎治療のアジア市場規模・予測 ・肝炎治療の日本市場規模・予測 ・肝炎治療の中国市場規模・予測 ・肝炎治療のインド市場規模・予測 ・肝炎治療の中東市場規模・予測 ・肝炎治療のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Hepatitis Therapeutics Market: Overview
This report analyzes the current and future scenario of the global hepatitis therapeutics market. Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favorable government support are the major drivers of the global market.
The global hepatitis therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on disease type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises company profiles with product portfolio to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by region, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hepatitis therapeutics market.
Global Hepatitis Therapeutics Market: Key Segments
The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region. In terms of disease type, the global market has been segmented into hepatitis A, hepatitis B, hepatitis C, and others. Based on drug class, the global hepatitis therapeutics market has been categorized into nucleotide analog reverse transcriptase inhibitor, NS5A inhibitor, multi- class combination, nucleotide analog NS5B polymerase inhibitor, interferon & ribavirin, and others. Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others. The market value and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Hepatitis Therapeutics Market: Regional Outlook
The global hepatitis therapeutics market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). The Market Value and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global hepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, recent developments, and SWOT analysis. Major companies profiled in the report are Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., F. Hoffmann-La Roche, Ltd., LAURUS Labs, AbbVie Inc., Hetero Healthcare Limited, Zydus Cadila, Cipla, Inc., and NATCO Pharma Limited.
The global hepatitis therapeutics market has been segmented as below:
Global Hepatitis Therapeutics Market, by Disease
Hepatitis A
Hepatitis B
Hepatitis C
Others
Global Hepatitis Therapeutics Market, by Drug Class
Nucleotide Analog Reverse Transcriptase Inhibitor
NS5A Inhibitor
Multi Class Combination
Nucleotide Analog NS5B Polymerase Inhibitor
Interferon & Ribavirin
Others
Global Hepatitis Therapeutics Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Therapeutics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Pipeline Analysis
5.2.New Product Launch, Approvals & Patent Expiry
5.3.Regulatory Scenario
6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Disease Type, 2016–2026
6.2.1. Hepatitis A
6.2.2. Hepatitis B
6.2.3. Hepatitis C
6.2.4. Others
6.3. Market Attractiveness, by Disease Type
7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class
7.1. Introduction & Definition
7.2. Market Value Forecast, by Drug Class, 2016–2026
7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.2.2. NS5A Inhibitor
7.2.3. Multi Class Combination
7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.2.5. Interferon & Ribavirin
7.2.6. Others
7.3. Market Attractiveness, by Drug Class
8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2016–2026
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
9.1. Market Value Forecast, by Region
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Market Attractiveness, by Country/Region
10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Disease Type, 2016–2026
10.2.1. Hepatitis A
10.2.2. Hepatitis B
10.2.3. Hepatitis C
10.2.4. Others
10.3.Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.3.2. NS5A Inhibitor
10.3.3. Multi Class Combination
10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.3.5. Interferon & Ribavirin
10.3.6. Others
10.4.Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5.Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6.Market Attractiveness, Analysis
10.6.1.By Disease Type
10.6.2. B Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Disease, 2016–2026
11.2.1. Hepatitis A
11.2.2. Hepatitis B
11.2.3. Hepatitis C
11.2.4. Others
11.3.Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.3.2. NS5A Inhibitor
11.3.3. Multi-class Combination
11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.3.5. Interferon & Ribavirin
11.3.6. Others
11.4.Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5.Market Value Forecast, by Country, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness, Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Disease Type, 2016–2026
12.2.1. Hepatitis A
12.2.2. Hepatitis B
12.2.3. Hepatitis C
12.2.4. Others
12.3.Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.3.2. NS5A Inhibitor
12.3.3. Multi-class Combination
12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.3.5. Interferon & Ribavirin
12.3.6. Others
12.4.Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Value Forecast, by Country, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness, Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Disease Type, 2016–2026
13.2.1. Hepatitis A
13.2.2. Hepatitis B
13.2.3. Hepatitis C
13.2.4. Others
13.3.Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.3.2. NS5A Inhibitor
13.3.3. Multi-class Combination
13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.3.5. Interferon & Ribavirin
13.3.6. Others
13.4.Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Value Forecast, by Country, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness, Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1.Introduction
14.2.Market Value Forecast, by Disease Type, 2016–2026
14.2.1. Hepatitis A
14.2.2. Hepatitis B
14.2.3. Hepatitis C
14.2.4. Others
14.3.Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.3.2. NS5A Inhibitor
14.3.3. Multi-class Combination
14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.3.5. Interferon & Ribavirin
14.3.6. Others
14.4.Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5.Market Value Forecast, by Country, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.5. Rest of Middle East & Africa
14.6.Market Attractiveness, Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1.Market Share Analysis, by Company (2017)
15.2. Company Profiles
15.2.1. Gilead Sciences, Inc.
15.2.2. F. Hoffmann-La Roche, Ltd.
15.2.3. Bristol Myers Squibb
15.2.4. Merck & Co., Inc.
15.2.5. AbbVie Inc.
15.2.6. NATCO Pharma Limited
15.2.7. Zydus Cadila
15.2.8. Hetero Healthcare Limited
15.2.9. LAURUS Labs
15.2.10. Cipla, Inc.
Table 01: Pipeline Analysis
Table 02: Pipeline Analysis
Table 03: Pipeline Analysis
Table 04: New Product Launch, Approvals & Patent Expiry
Table 05: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026 2016–2026
Table 06: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 07: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 10: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 11: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 12: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 13: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 14: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 15: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 16: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 17: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 18: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 19: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 20: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 21: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 22: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 23: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 24: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 25: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 26: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 27: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 28: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026